Table 2.

Parameters of thrombin generation according to hormone therapy

	No hormone therapy (n=36)	Transdermal estrogens + progesterone (n=29)	Transdermal estrogens + norpregnanes (n=33)#
Lag Time-APC (min)	2.02 (0.38)	1.92 (0.59)	1.79 (0.41)
Lag Time+APC (min)	2.44 (0.77)	2.64 (0.65)	2.82 (0.63)
Peak height-APC (nM IIa)	280.42 (22.71)	281.21 (28.59)	280.61 (27.38)
Peak height+APC (nM IIa)	16.15 (14.47)	15.03 (13.63)	23.79 (18.84) * £
ETP-APC (nM/min)	1639 (158)	1668 (196)	1693 (188)
ETP+APC (nM/min)	134 (102)	133 (104)	197 (132) * £
APCsrETP	1.00 (0.63)	0.98 (0.72)	1.64 (1.17) ** ££

Mean values (SD) adjusted for age and body-mass index

^#Women received either nomegestrol acetate (n=19) or promegestone (n=14)

Comparison to non-user group:

^*p<0.05;

^**p<0.01

Comparison to the group treated by transdermal estrogens combined with micronized progesterone:

^£p<0.05;

^££p<0.01